This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orchekowski, R. Articles by Haab, B. B. Search for Related Content PubMed PubMed Citation Articles by Orchekowski, R. Articles by Haab, B. B. Related Collections Early Detection Early Detection: Biomarkers: Discovery, Methodology, Validation

Antibody Microarray Profiling Reveals Individual and Combined Serum Proteins Associated with Pancreatic Cancer

¹ Van Andel Research Institute, Grand Rapids, Michigan; ² Fred Hutchinson Cancer Research Center, Seattle, Washington; ³ Evanston Northwestern Healthcare, Evanston, Illinois; and ⁴ University of Michigan Medical School, Ann Arbor, Michigan

Requests for reprints: Brian B. Haab, Van Andel Research Institute, 333 Bostwick Northeast, Grand Rapids, MI 49503. Phone: 616-234-5268; Fax: 616-234-5269; E-mail: Brian.Haab{at}vai.org.

We used antibody microarrays to probe the associations of multiple serum proteins with pancreatic cancer and to explore the use of combined measurements for sample classification. Serum samples from pancreatic cancer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subjects (n = 50) were probed in replicate experiment sets by two-color, rolling circle amplification on microarrays containing 92 antibodies and control proteins. The antibodies that had reproducibly different binding levels between the patient classes revealed different types of alterations, reflecting inflammation (high C-reactive protein, -1-antitrypsin, and serum amyloid A), immune response (high IgA), leakage of cell breakdown products (low plasma gelsolin), and possibly altered vitamin K usage or glucose regulation (high protein-induced vitamin K antagonist-II). The accuracy of the most significant antibody microarray measurements was confirmed through immunoblot and antigen dilution experiments. A logistic-regression algorithm distinguished the cancer samples from the healthy control samples with a 90% and 93% sensitivity and a 90% and 94% specificity in duplicate experiment sets. The cancer samples were distinguished from the benign disease samples with a 95% and 92% sensitivity and an 88% and 74% specificity in duplicate experiment sets. The classification accuracies were significantly improved over those achieved using individual antibodies. This study furthered the development of antibody microarrays for molecular profiling, provided insights into the nature of serum-protein alterations in pancreatic cancer patients, and showed the potential of combined measurements to improve sample classification accuracy.

This article has been cited by other articles:

				C. Lausted, Z. Hu, and L. Hood Quantitative Serum Proteomics from Surface Plasmon Resonance Imaging Mol. Cell. Proteomics, December 1, 2008; 7(12): 2464 - 2474. [Abstract] [Full Text] [PDF]

				H. K. Roy and J. D. Khandekar Biomarkers for the Early Detection of Cancer: An Inflammatory Concept Arch Intern Med, September 24, 2007; 167(17): 1822 - 1824. [Full Text] [PDF]

				K. Heikkila, S. Ebrahim, and D. A Lawlor A systematic review of the association between circulating concentrations of C reactive protein and cancer J Epidemiol Community Health, September 1, 2007; 61(9): 824 - 833. [Abstract] [Full Text] [PDF]

				P. Ellmark, J. Ingvarsson, A. Carlsson, B. S. Lundin, C. Wingren, and C. A. K. Borrebaeck Identification of Protein Expression Signatures Associated with Helicobacter pylori Infection and Gastric Adenocarcinoma Using Recombinant Antibody Microarrays Mol. Cell. Proteomics, September 1, 2006; 5(9): 1638 - 1646. [Abstract] [Full Text] [PDF]